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Objective: This study aimed to explore the prevalence of CVDs risk factors in people 
with severe mental illness (SMI), estimating its weight on related risks in Southern 
Europe, an area with distinct dietary traditions. People with SMI may be more likely 
than general population to have high prevalence of risk factors for cardiovascular 
diseases (CVDs), due to several reasons, including poor health behaviours and 
psychopharmacological medications. 
Method: A cross-sectional study has been conducted, comparing inpatients with and 
without SMI. Univariate and multivariate analyses and logistic regression models have 
been carried out, exploring the effect of SMI on the prevalence of CVDs risk factors. 
Results: Although obesity and hypertriglyceridemia were more prevalent among people 
with SMI, controlling for relevant confounders in multivariate analyses we could not 
detect any significant difference. 
Conclusions: People with SMI may not necessarily have higher CVDs risk, as 
compared with general population. Mediterranean healthy dietary habits, universal 
health coverage, families providing strong support, all are possible explanations for our 
findings. Further research is needed, exploring different mechanisms, with more 
detailed biological and genetics measures. 
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Over the past years, evidence has been accumulated showing that frequency of 
cardiovascular diseases (CVDs) risk factors -including hypertension, smoking, poor 
diet, obesity, lack of exercise, diabetes mellitus, and dyslipidemia- are often higher 
among people suffering from psychiatric disorders than in general population [e.g., 1-5]. 
In particular, people with severe mental illness (SMI) show a threefold increase in risk 
of developing diabetes mellitus as compared to general population [6,7]. Smoking 
prevalence can be up to four times higher among people with SMI than in general 
population [8]. Several studies report higher prevalence also of hypertension, 
dyslipidemia and metabolic syndrome among people with SMI, though differences do 
not always reach statistical significance [6,7]. Furthermore, in people with SMI as 
compared with general population, morbidity related to CVDs is up to three times 
higher [9], and this issue - along with associated mortality [10] - is cause for concern 
because of reduced life expectancy [11]. 
Several hypotheses have been proposed in order to explain the additional load in terms 
of CVDs risk factors in people with SMI [12]. SMI itself may genetically bring 
increased CVDs risk factors [13]. Also, unhealthy lifestyle and poor compliance to 
medications prescribed for physical illnesses [14] are likely to be involved. However, 
antipsychotics and other psychotropic medications by themselves play a major role, in 
hyperglycemia, increased serum cholesterol and weight gain [15]. Finally both 
clinicians and health services may pose barriers to accessing appropriate care, with 
people with SMI receiving physical treatment poorer than general population [12], 
despite lifestyle modification interventions and preventive programs maybe effective 
also for this special population [16]. 
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Each of described etiological possibilities may be illuminated by studying them in 
geographical contexts with particular attributes. The population of countries in Southern 
Europe usually show reduced CVDs-related mortality rates, possibly because of 
generally healthy Mediterranean dietary habits, though other risk factors like smoking 
are more prevalent than in the U.S. [17]. This region thus offers opportunities for 
studying the prevalence of CVDs risk factors in relation to family and personal history, 
psychotropic medication and adverse health behaviors in people with SMI. If these are 
important causes of CVDs risk factors, the relative odds in people with SMI should be 
increased in the context of healthy eating habits at the population level.  
Understanding variations in prevalence of CVDs risk factors in people with SMI is 
important for several major reasons. First, geographical variation in CVDs risk factors 
in people with SMI is important in appreciating the impact of local social circumstances 
on prevalence, and whether variations are just as apparent as in the general population 
[18]. Secondly, good prevalence data are crucial to planning basic primary prevention 
and routine diagnostic screening for CVDs risk factors in this vulnerable group. Finally, 
in etiological terms, the relative roles of antipsychotic medication and of adverse health 
behaviors in relation to CVDs risk factors can be better studied in a context with 
traditionally healthy dietary habits. Unfortunately, earlier investigations in Southern 
Europe have been influenced by methodological issues. Samples have often been based 
on clinical convenience [19], and control groups have been unsuitable for a number of 
reasons, lacking relevant healthy comparison groups [20], using comparison samples 
from different populations [21] or based on large existing administrative databases [22].  
This study aims to explore the prevalence of CVDs risk factors in a representative 
cohort of people with SMI in Italy. We hypothesized that after adjusting for relevant 
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clinical and social variables, even in this healthy dietary context people with SMI would 
have CVDs risk factors prevalence rates significantly higher than those without mental 
disorders.  
Methods 
Setting and study design  
We carried out a cross-sectional comparative study among people with and without 
SMI, recruited from inpatients admitted to San Gerardo University Hospital, whose 
1,105 beds -with a comprehensive range of medical and surgical inpatient services- 
include a 20 beds ward for acute mental health care, serving a catchment area of 
319,000 inhabitants. The study took place in Monza-Brianza (MB), a mixed urban and 
rural province in Northern Italy, which comprises relatively wealthy districts, as 
compared with the national average based on 2011 annual Census data [23]. The 
research project complied with the principles of the Declaration of Helsinki regarding 
medical research in humans [24]. The local research ethics committee approved the 
study (code “Non solo mente”). 
Sampling and procedures  
SMI was defined according to a modified version of the US Substance Abuse and 
Mental Health Service Administration definition [25], by requiring at least one 12-
month DSM-IV/SCID diagnosis other than a substance use disorder (i.e. Psychotic 
Disorders, Bipolar Disorder and Major Depressive Disorder with Psychotic Features), 
along with a Global Assessment of Functioning (GAF) score of less than 60 during the 
worst month of the past year [26,27]. All patients consecutively admitted between 
March 2011 and February 2012 to the mental health inpatient ward and with a SMI 
diagnosis, were approached for their informed and signed consent to the study. If they 
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agreed, they were interviewed on the day before their planned discharge in order to 
check their diagnosis. Fully trained consultant psychiatrists administered the 12-month 
patient version of the SCID-I (Structured Clinical Interview for DSM-IV [28]) to 
identify SMI diagnoses within this group. Patients’ functioning was assessed clinically 
and using medical records. In the same period, all inpatients from the maxillofacial 
surgery unit – consecutively admitted for planned (not emergency) cosmetic surgical 
treatment for minor or mild car accidents– were invited to participate in order to build 
an eligible list for the comparison group. We chose this clinical population as unlikely 
to suffer more from chronic physical disorders than the general population. To be 
eligible for recruitment, people from the index and the comparison groups had to be at 
least 18 years old and living in a private residence (rather than in an institutional 
setting). People from the comparison group were excluded if they had received a formal 
psychiatric diagnosis, had ever taken an antipsychotic, a mood stabilizer or an 
antidepressant medication, or were on the caseload of any mental health service 
nationwide. CVDs risk factors were defined according to cut-off values of the third 
report of the National Cholesterol Education Program Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults [29]: 
 obesity (Body Mass Index -BMI ≥30 kg/m2); 
 hypertriglyceridemia (fasting triglycerides concentration ≥200 mg/dl); 
 hypertension (systolic/diastolic blood pressure ≥140/90 mmHg and/or on 
antihypertensive medication); 
 low density lipoprotein (LDL) cholesterol ≥160 mg/dl); 
 hyperglycemia (fasting blood glucose level ≥126 mg/dl or on insulin or 
hypoglycemic medication). 
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Finally, we estimated total cholesterol/HDL cholesterol ratios, and the whole sample 
was dichotomized around the relevant median value, giving a high and a low ratio 
category [30]. 
Data collection  
Patients’ data were obtained for index and control subgroups from both clinical records 
and interviews. We collected general socio-demographic information for each 
participant. We systematically recorded clinical data including current smoker’s status 
[31], family and personal history of CVDs (i.e. myocardial infarction, acute heart 
failure, acute coronary syndrome, and stroke), diagnoses of hypertension, dyslipidemia 
and diabetes mellitus. For SMI inpatients we gathered information about current 
medication, and amounts of antipsychotic agents prescribed in the previous six months 
were converted in average chlorpromazine (CPZ) equivalent doses, according to the 
best available sources [32-35], though the validity of this measure is not entirely clear 
[e.g., 36]. Mood stabilizer and antidepressant medications were also collected. 
As part of the routine admission procedure, height and weight (on electronic scales, 
with the minimal necessary clothing) were measured, and BMI was calculated. If 
feasible, we retrieved waist circumference with a non-elastic measuring tape around the 
abdomen at the approximate midpoint between the lower margin of the last palpable rib 
and the top of the iliac crest [37]. We measured blood pressure at the beginning and end 
of the interview using an automated sphygmomanometer, with the patient in a sitting 
position after at least 5 minutes resting, and the mean value was determined. Blood 
samples were drawn around 8.00 am, and the patients had fasted at least for the previous 
10 hours. Plasma levels of glucose, triglycerides and total, LDL, HDL cholesterol were 
analyzed. All serum analyses were performed using standard methods on a Cobas 8000, 
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module c701 (Roche Diagnostics, Basel, Switzerland) at the Department of Clinical 
Biochemistry of San Gerardo University Hospital, Monza (MB), Italy.  
Statistical analysis  
Statistical analyses were completed using Stata version 10.0 SE. We performed 
comparative analyses between two samples, each one drawn with a simple random 
sampling technique from the enrolled populations. Further details on sampling and 
randomization procedures have been described elsewhere [38]. 
We carried out univariate analyses to identify patients’ attributes characteristic of SMI. 
The normality of continuous data was checked with Shapiro-Wilk’s test. If the variances 
of the two subgroups examined were not homogeneous, we used the t-test for unequal 
variances and the Welch’s approximation of the degrees of freedom. Student’s t-test 
was performed for normally distributed continuous data. Chi-square and Fisher’s exact 
tests were used for categorical variables. As regards the effect of SMI on the prevalence 
of CVDs risk factors we followed a structured approach. First we estimated unadjusted 
ORs (95% CIs) for each CVD risk factor. Then, we added chlorpromazine equivalent 
dose as possible explanation for the increased rates of CVD risk factors in people with 
SMI, using Sobel–Goodman tests for mediation as framed in the sgmediation command 
in Stata. We used mediation analyses to test whether the relationship between SMI 
(independent variable) and each CVD risk factor (dependent variables) is direct or 
whether the mediator of chlorpromazine equivalent dose accounts for the relationship 
between them. If the association between SMI and each CVD risk factor is not reduced 
by a significant amount (partial mediation) by the mediator chlorpromazine equivalent 
dose, all that can be inferred is a direct effect of SMI on CVD risk factors. This would 
justify carrying out logistic regressions of the effect of SMI on the prevalence of 
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relevant CVDs risk factors, controlling for chlorpromazine equivalent dose as well as 
for age and gender. Finally we carried out logistic regressions of the effect of SMI on 
the prevalence of relevant CVDs risk factors, controlling for all sociodemographic and 
clinical covariates that were significantly (p<0.1) related in the univariate analyses.  
Results 
Characteristics of participants 
In total, 298 SMI patients and 264 comparison group patients were initially identified, 
of whom 208 and 196 were found to be eligible in the SMI and the comparison group 
respectively, all belonging to the white Italian ethnic group. None of the users screened 
for eligibility refused to participate in the study. Valid data were available for 119 
patients with SMI (Psychotic Disorders=82, Bipolar Disorders=31; Major Depressive 
Disorder with Psychotic Features=6) and 119 without SMI. The socio-demographic and 
clinical characteristics associated with SMI are summarized in Table 1. People with 
SMI were significantly more often males and current smokers but less married or 
cohabiting and fewer participants were employed. They also had mean levels of BMI, 
waist circumference, fasting triglycerides and total/HDL cholesterol ratio significantly 
higher than controls. They also showed significantly lower mean systolic blood 
pressure. Other variables did not reach statistical significance. In total, 115 out of 119 
patients (97%) in the SMI group were taking antipsychotics, 110 of which were atypical 
(26 Risperidone, 18 Quetiapine, 32 Olanzapine, 12 Clozapine, 10 Aripiprazole, 6 
Paliperidone, 6 Ziprasidone). The median chlorpromazine dose was 242 mg 
(interquartile range (IQR) 150–483 mg).  
TABLE 1 about here 
Multivariate analysis 
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In relation to the main CVDs risk factors, as defined by NCEP ATP III, only prevalence 
of obesity and hypertriglyceridemia were higher in those with SMI than in those without 
(Table 2). We then tested our specific hypotheses relating to potential mediator role of 
antipsychotic medication dose of the relationship between SMI and each CVDs risk 
factor. However, the proportion of the effect of SMI on each CVDs risk factor that was 
mediated by antipsychotic medication dose was minuscule, and not statistically 
significant: virtually all the effect was, therefore, direct. Thus, in our data, there is no 
evidence that antipsychotic medication dose can explain the excess of CVDs risk factors 
in people with SMI. Thus it was justifiable to add in the logistic regression models, age, 
gender, and chlorpromazine equivalent as covariates. The magnitude of our results 
changed, with hypertriglyceridemia remaining significantly higher, as well as total 
cholesterol/HDL cholesterol ratio, in people with SMI. Finally, ORs were adjusted for 
all sociodemographic and clinical covariates that were significantly related in the 
univariate analyses to each risk factor (these differed slightly in relation to the different 
factors but with appreciable overlap). However, none of CVDs risk factors maintained 
conventional levels of significance, with hypertriglyceridemia and total /HDL 
cholesterol ratio, showing just a marginal trend. 




We analyzed an epidemiologically representative random sample of inpatients with 
SMI. An appropriate comparison group was established and chosen. DSM-IV research 
diagnoses for SMI were based on formal diagnostic interviews. We were thus able to 
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study SMI in relation to differences in rates of CVDs risk factors in a region with 
distinct dietary traditions but also poor healthy behaviors such as smoking. The absence 
of mediation by antipsychotic dose may suggest that, at the population level at least, 
such drugs do not contribute much to the excess, or perhaps that much of the medication 
effect is already apparent at low dosage. People with SMI in our sample were 
significantly more often current smokers and also had mean levels of BMI, waist 
circumference, fasting triglycerides and total/HDL cholesterol ratio significantly higher 
than controls. They also showed significantly lower mean systolic blood pressure. 
Though in the univariate analyses our data showed that hypertriglyceridemia and total 
cholesterol/HDL cholesterol ratio were significantly higher in people with SMI, none of 
CVDs risk factors maintained conventional levels of significance when controlling for 
all sociodemographic and clinical covariates that were significantly related in the 
univariate analyses to each risk factor. However, adjusting for relevant covariates, we 
could not find any association, though hypertriglyceridemia and total/HDL cholesterol 
ratio showed a non-significant trend in people with SMI.  
Our findings do not support previous research from other Western countries. SMI has 
been found to be associated with obesity, smoking, diabetes mellitus, hypertension and 
metabolic syndrome [10,14,39], and generally the prevalence of CVDs risk factors 
among people with SMI is high [40]. However, obesity and hypertriglyceridemia do not 
seem inherent to SMI, since it can be effectively managed by specific interventions, 
including dietary education and physical activity [41], but also other types of 
interventions such as health education, smoking cessation, and changes in health care 
organization [42]. Indeed also a relatively recent meta-analysis found that only diabetes 
mellitus was strongly associated with SMI, while hypertension and dyslipidemia were 
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not, even if studies about the latter two factors were too heterogeneous or inadequate to 
draw firm conclusions [7].  
There are several possible alternative explanations for our findings. First National 
Health System universal health coverage, available to all, regardless of wealth, may 
make possible effective prevention also for people with SMI in terms of CVDs risk 
factors [43]. However, comparable data, from well established NHS (U.K. and 
Norway), still show CVDs risk factors rates significantly higher in people with SMI 
than in general practice comparison groups [30,44]. Secondly, in Italy, as in other 
Mediterranean countries, family provides strong support for people with SMI [45] 
perhaps positively influencing dietary habits. Finally, Mediterranean healthy dietary 
habits could be important protective factors, reducing CVDs risk factors, such as 
hypertriglyceridemia and insulin resistance [38,46]. However, findings on CVDs risk 
factors rates in people with SMI from other Mediterranean countries are not 
homogeneous, and our data seem comparable with some [20] but not all [19,21,22,47] 
studies. Along with methodological issues, it may well be that Mediterranean healthy 
dietary habits in different Southern Europe countries are influenced by others factors 
such as area-level socio-economic position and wealth [48].  
Limitations  
The procedure for identifying SMI was based on the use of a standardized instrument, 
the SCID though the reliability of ratings was not formally established during the study. 
We have addressed selection bias at the stage of design for the index and the 
comparison groups (random sampling) and the role of possible confounders at the stage 
of analysis for the whole sample (adjusting for a selected set of variables). While 
attempts were made to guarantee comparable recruitment procedures, acute-phase 
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treatment might have exacerbated the metabolic disturbances, and in general our results 
may not be generalizable beyond hospitalized populations, that could possibly 
experience poor social or familial support, which could thereby influence their diet. 
Given the cross-sectional design of our study, no reverse causality is allowed, though it 
is unlikely that CVD risk factors may cause SMI. Prospective time series data, with 
comprehensive assessment of lifetime exposure to antipsychotics, are needed to answer 
the question of causation, and we could consider for our analyses only 
psychopharmacological medications prescribed in the last six-months before admission, 
not to mention unknown compliance and other comorbid conditions [49,50]. However, 
though differences emerged between groups with and without SMI, we could study the 
differential confounding effects, and their mechanisms, of antipsychotic medication, of 
health behaviors such as smoking, and an indirect indicator of inherited risk (family 
history of CVDs, though it could just as likely be due to shared environment as 
genetics). The setting, the manner of delivery of interventions and the exclusion criteria 
are relatively similar to those found elsewhere, allowing reasonable generalizability to 
similar populations in Western countries. Nevertheless, as CVDs risk factors were 
assessed in treated populations, findings might not be the same in people out of contact 
with services. Also, we did not collect information on dietary habits of our sample, 
although poor diet partly accounts for the higher incidence of metabolic abnormalities 
among people with schizophrenia [1]. 
Conclusions 
In a relatively wealthy area, with traditionally healthy dietary habits, CVDs risk factors 
among people with SMI may not be more prevalent than in the general population. 
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Further research in Southern Europe countries should consider different mechanisms, 
with more detailed biological and genetics measures, in order to explore other potential 
protective factors, specific of people with SMI and shared with general population.  
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Table 1. Socio-demographic and clinical characteristics associated with severe mental illness (SMI) 





Age: Mean (SD), yrs 47.2 (14.8) 49.4 (19.7) nsa 
Gender: No. (%) Male 51 (42.9) 65 (54.6) 0.069* 
Education: No. (%) ≥High school  58 (48.7) 56 (47.1) ns* 
Married/cohabiting: No. (%) 28 (23.5) 64 (54.7) <0.001* 
Ordinary employed: No. (%) 58 (48.7) 104 (87.4) <0.001* 
BMI1: Mean (SD), kg/m2 25.5 (6.6) 24.2 (4.3) 0.075b  
Waist circumference: Mean(SD), cm 95.2 (17.1) 91.0 (14.8) 0.052† 
SBP2: Mean (SD), mmHg 116.9 (11.7) 122.3 (14.2) 0.001c 
DBP3: Mean (SD), mmHg 75.2 (7.8) 76.3 (8.8) ns† 
Fasting glucose: Mean (SD), mg/dl 93.0 (20.4) 97.2 (22.4) ns† 
Triglycerides: Mean (SD), mg/dl 121.9 (91.5) 97.9 (52.9) 0.014d 
Total cholesterol: Mean (SD), mg/dl 183.3 (46.8) 179.7 (40.4) ns† 
LDL4: Mean (SD), mg/dl 110.9 (47.1) 108.4 (36.1) nse 
HDL5: Mean (SD), mg/dl 48.4 (14.8) 51.5 (14.9) ns† 
Total cholesterol/HDL ratio: Mean (SD) 4.1 (1.6) 3.7 (1.4) 0.079† 
Smoking: No (%) 77 (64.7) 63 (52.9) 0.065* 
History of CVDs: (No. %) 11 (9.2) 14 (11.8) ns* 
Family history of CVDs: (No. %) 44 (37.0) 47 (39.5) ns* 
1Body mass index; 2Systolic blood pressure; 3Diastolic blood pressure; 4Low density lipoprotein; 5High density lipoprotein. 
Student’s t test with unequal variances; Welch's degrees of freedom a220.542; b203.929; c229.217; d190.333; e222.836 
* Pearson’s χ2 test with 1 d.f. †Student’s t test (df=236 for all) 
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Table 2. Association between CVDs risk factors and SMI: univariate and multivariate analyses 
Variable Unadjusted OR 
(95% CI) 
OR adjusted for 
age, gender and 
CPZ† (95% CI) 
OR adjusted for age, 
gender, CPZ† and 
variables significant at 
the univariate level 
(95% CI) 
Obesity1 
SMI 21 (17.6 %) 
Non-SMI 10 (8.4 %) 
2.34 * 
(1.04-5.25) 






P =0.302  
Hypertension 
SMI 26 (21.8 %) 
Non-SMI 39 (32.7 %) 
0.57  
(0.32-1.03) 






P =0.230  
Hyperglycaemia 
SMI 13 (10.9 %) 
Non-SMI 16 (13.9 %) 
0.79  
(0.36-1.73) 






P =0.514  
Hypertriglyceridemia 
SMI 18 (15.1 %) 
Non-SMI 8 (6.7 %) 
2.47 * 
(1.03-5.93) 






P =0.055  
LDL Hypercholesterolemia 
SMI 14 (11.7 %) 
Non-SMI 13 (10.9 %) 
1.09  
(0.49-2.43) 





Total /HDL cholesterol ratio 
SMI 66 (55.5 %) 
Non-SMI 53 (44.5 %) 
1.55  
(0.93-2.60) 







†equivalent dose of chlorpromazine for antipsychotic. *Statistically significant; **No variable was significantly associated with 
LDL hypercholesterolemia at the univariate analysis. 
1Controlled for education, family history of cardiovascular disease, mood stabilizer medication; 2Controlled for family situation, 
education, current employment, history of cardiovascular disease, family history of cardiovascular disease;  3Controlled for family 
situation, history of cardiovascular disease, family history of cardiovascular disease; 4Controlled for smoking status, history of 
cardiovascular disease, mood stabilizer medications; 5Controlled for family situation, smoking status, antidepressant medications. 
 
 
